exelixis inc
(EXEL:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)

Executive Profile*

Background*

Dr. Gisela M. Schwab, M.D. has been Chief Medical Officer of Exelixis Inc., since September 2006 and its Executive Vice President since January 2008. Dr. Schwab served as Senior Vice President of Exelixis Inc. since September 2006. Dr. Schwab more than 20 years of experience in the development of oncology therapeutics. Dr. Schwab has extensive expertise in building and managing functional teams leading to worldwide product registration. Recently, she served as Senior ... Vice President and Chief Medical Officer of Abgenix, Inc. since January 2002, a human antibody- based drug development company that was acquired by Amgen, Inc. in January 2006. she led worldwide product development activities, including preclinical development; pharmacokinetics and toxicology; regulatory affairs and clinical development in diverse therapeutic areas, including hematology and oncology. She served as Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. Previously she served as vice president, clinical development, of Abgenix from 1999 to 2001. From 1992 to 1999 she held various roles of increasing responsibility at Amgen Inc., including Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. She serves as Director of Cellerant Therapeutics, Inc. Dr. Schwab has been Director of TopoTarget A/S since August 29, 2011. Dr. Schwab received her Doctor of Medicine degree from the University of Heidelberg, and has performed research in molecular biology at the National Cancer Institute in Bethesda, Maryland and is board certified in internal medicine and hematology and oncology and at the French National Institute for Health and Research in Paris.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
EXEL:US	$4.74 USD	-0.03

COMPETITOR COMPENSATION